Revolutionizing the treatment of chronic disease.
Leveraging our NanoPortal™ technology, we are developing a portfolio of highly differentiated products comprised of miniature, sub-dermal drug implants.
Our Pipeline
Management
Semaglutide
incretins*
Management
Exenatide
Semaglutide
Obesity
Exenatide
Management
Semaglutide
incretins*
Management
Exenatide
Semaglutide
Obesity
Exenatide
Management
Semaglutide
incretins*
Management
Exenatide
Semaglutide
Obesity
Exenatide
**In partnership with Okava Pharmaceuticals, Inc.
NPM-139 (Semaglutide Implant): Our Lead Program
A miniature, GLP-1 receptor agonist implant designed to address medication non-adherence and improve tolerability.
NPM-139, leveraging our NanoPortal™ technology, is designed to provide steady, long-term therapeutic delivery of semaglutide for at least six months.
By assuring medication adherence, NPM-139 may free patients with obesity from burdens associated with oral and injectable medications, as well as provide confidence to physicians, caregivers and loved ones that patients are receiving the intended therapeutic benefits from their medicine.
Target
Under investigation for chronic weight management/obesity.
Although the GLP-1 receptor agonist class has quickly outpaced previous anti-obesity medications due to superior efficacy and tolerability, medication non-adherence continues to affect an alarming number of patients – approximately 50%, including those taking daily pills. In fact, non-adherence may also contribute to the gap in real-world effectiveness compared to the efficacy reported from randomized, controlled, clinical trials.
Development
Our lead program is NPM-139 (semaglutide implant) currently under clinical-stage development for chronic weight management. SLIM-1™ is an on-going Phase 1 trial of NPM-139 designed to assess the safety, tolerability, and pharmacokinetics of low-doses of NPM-139 and Wegovy. Changes in weight will also be measured. This clinical trial is fully enrolled, and all 20 participants have been dosed successfully. Top-line data from the SLIM-1 trial are expected in November 2026 and efforts supporting a dose-ranging Phase 2 trial are underway with trial initiation anticipated in 2027.
NPM-133 Overview
A miniature, GLP-1 receptor agonist implant designed for patients living with type 2 diabetes.
Built with our NanoPortal™ technology, NPM-133 is designed to provide steady, long-term therapeutic delivery of semaglutide for at least six months.
For patients with type 2 diabetes, the health risks associated with missed doses of prescribed medications can be severe. NPM-133, currently in development, offers the potential for these patients to receive the full therapeutic benefits of semaglutide treatment over six-months or more without interruption, providing convenience and peace-of-mind.
